Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
Grifols has started dosing patients in two Phase 3 clinical trials, SIGMA and XPERT, aimed at expanding the U.S. label indications for its flagship immunoglobulin therapies, GAMUNEX-C and XEMBIFY. The SIGMA trial evaluates GAMUNEX-C combined with standard treatment in patients with secondary immunodeficiency linked to hematologic cancers, while the…